2021
DOI: 10.1016/j.apsb.2021.02.003
|View full text |Cite
|
Sign up to set email alerts
|

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Abstract: Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
12
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 118 publications
0
12
0
Order By: Relevance
“…Although there are multiple treatments recommended for NSCLC, chemotherapy remains the main treatment modality [ 15 ]. With respect to chemotherapy, pemetrexed is considered the preferred drug for advanced NSCLC, both as neoadjuvant and adjuvant therapy due to its favorable therapeutic benefit [ 16 , 17 ], even in patients with brain metastases [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although there are multiple treatments recommended for NSCLC, chemotherapy remains the main treatment modality [ 15 ]. With respect to chemotherapy, pemetrexed is considered the preferred drug for advanced NSCLC, both as neoadjuvant and adjuvant therapy due to its favorable therapeutic benefit [ 16 , 17 ], even in patients with brain metastases [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…It has been shown recently that TUBB mRNA expression is upregulated in breast cancer patients resistant to chemotherapy [ 10 , 15 ]. Mutations in TUBB have been shown to demonstrate resistance to chemotherapy [ 16 , 17 ], in which the l240I mutation shows specific resistance to vincristine [ 18 ]. In contrast, A248V, A185T, and R306C mutations confer resistance to paclitaxel [ 17 ].…”
Section: Introductionmentioning
confidence: 99%
“…Even though multiple treatments are recommended for NSCLC patients, chemotherapy is still the main modality for NSCLC patients[ 15 , 16 ]. With respect to chemotherapy, pemetrexed is regarded as the preferred drug for advanced NSCLC as neoadjuvant and adjuvant therapy for its therapeutic benefit and good tolerability [ 17 , 18 ], even in patients with brain metastases [ 19 ]. Recently, clinical evidence further revealed the potential of pemetrexed-EGFR TKIs combination.…”
Section: Introductionmentioning
confidence: 99%